People News: Abbott Labs and Lux Biosciences

Abbott Laboratories executive vice president of pharmaceuticals Olivier Bohuon is leaving the company to become CEO at Pierre Fabre Group, a French pharmaceutical company, beginning September 1. Richard Gonzalez, a former president and COO at Abbott, will lead Abbott's pharmaceutical division on an interim basis, according to an Associated Press report. Abbott's pharmaceutical division is responsible for the lion's share of the company's total revenue, due mostly to Humira, a blockbuster injection indicated for rheumatoid arthritis, Crohn's disease and other inflammatory conditions. The pharmaceuticals division pulled in $4.1 billion in sales for the first quarter of 2010, according to the AP.

Lux Biosciences hired Dean Mitchell as president and CEO. Mitchell had been president and CEO of Alpharma before that company was acquired by King in 2008.

You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.